Wells Fargo’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-30,000
Closed -$4.37M 7124
2024
Q3
$4.37M Hold
30,000
﹤0.01% 2445
2024
Q2
$4.12M Hold
30,000
﹤0.01% 2407
2024
Q1
$4.12M Buy
+30,000
New +$4.1M ﹤0.01% 2411
2022
Q4
Sell
-17,000
Closed -$1.99M 7574
2022
Q3
$1.99M Buy
+17,000
New +$2.11M ﹤0.01% 2744
2020
Q1
Sell
-81,800
Closed -$521K 6456
2019
Q4
$521K Hold
81,800
﹤0.01% 4328
2019
Q3
$45K Hold
81,800
﹤0.01% 5586
2019
Q2
$390K Buy
+81,800
New +$8.7M ﹤0.01% 4555
2018
Q2
Sell
-10,500
Closed -$16K 6426
2018
Q1
$16K Sell
10,500
-176,000
-94% -$19.5M ﹤0.01% 5856
2017
Q4
$68K Buy
186,500
+138,200
+286% +$14.8M ﹤0.01% 5450
2017
Q3
$16K Sell
48,300
-48,300
-50% -$5.16M ﹤0.01% 5768
2017
Q2
$239K Sell
96,600
-27,900
-22% -$2.75M ﹤0.01% 4669
2017
Q1
$19K Buy
124,500
+24,900
+25% +$2.38M ﹤0.01% 5720
2016
Q4
$20K Buy
99,600
+49,800
+100% +$4.53M ﹤0.01% 5627
2016
Q3
$33K Buy
49,800
+24,900
+100% +$2.37M ﹤0.01% 5452
2016
Q2
$7K Buy
24,900
+9,300
+60% +$834K ﹤0.01% 5747
2016
Q1
$14K Buy
+15,600
New +$1.4M ﹤0.01% 5591

Other funds holding IBB

Wells Fargo's IBB Position: Q2 2026 in Review

Wells Fargo increased its iShares Biotechnology ETF (IBB) stake by 21% in Q2 2026, buying an estimated $30.1M and bringing the position to 1,029,643 shares worth $196M. The position accounts for 0.03% of the portfolio, ranked #436.

Wells Fargo first reported a position in IBB in Q2 2013 and has held it in 53 quarters since. 956 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Wells Fargo held 1,029,643 shares of iShares Biotechnology ETF worth $196M as of Q2 2026.
  • Wells Fargo bought 175,298 iShares Biotechnology ETF shares in Q2 2026, an estimated $30.1M.
  • iShares Biotechnology ETF made up 0.03% of Wells Fargo's portfolio in Q2 2026, its #436 holding.
  • Wells Fargo first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 53 quarters since.
  • 956 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.